-
26
2020.11
TOT BIOPHARM Unveils Results of Phase III Clinical Trial of TAB008（Bevacizumab Injection）in ESMO ASIA for the First Time
-
16
2020.10
TOT BIOPHARM International Company Limited 東曜藥業股份有限公司
-
14
2020.08
TOT BIOPHARM Announces 2020 Interim Results
-
23
2020.07
TOT BIOPHARM Announces First Patient Dosed in Phase III Clinical Trial of ADC Candidate TAA013
-
21
2020.04
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin®) Meets Primary Endpoint in Phase III Clinical Trial
-
21
2020.04
TOT BIOPHARM International Company Limited TOT BIOPHARM Appoints Dr. Liu Jun as Chief Operating Officer
-
18
2020.03
TOT BIOPHARM International Company Limited TOT BIOPHARM Announces 2019 Annual Results
-
30
2020.09
Happy Mid-autumn Festival!
-
25
2018.05
Science and technology for huai, yao see the future!
-
05
2017.01
TOT BIOPHARM signed an exclusive licensing agreement for monoclonal antibody TAB014 with li's pharmaceutical company
-
19
2013.04
Wang rongping carried out special research on the "four new highlands" in suzhou
-
27
2019.09
Be in the lead! TOT BIOPHARM will release ADC drug TAA013 clinical phase I data
-
20
2018.12
The first subjects in the phase I study of TOT BIOPHARM antibody-coupled drug were enrolled for administration
-
14
2018.09
TAA013, an antibody coupled drug of TOT BIOPHARM has been approved clinically
-
13
2018.09
Touching life - remember cancer star story reading club
-
08
2018.08
TOT completed the B round financing of 102 million us dollars.
